1.A Case of Recurrent Pneumatosis Cystoides Intestinalis Associated with Recurrent Pneumoperitoneum.
Ju Yee PARK ; Jae Young YOON ; Sun Yang MIN ; Seung Kwon HONG ; Ju Sang PARK ; Eun Jeong JANG ; Hyun Wook BAIK ; Sang Jong PARK
The Korean Journal of Gastroenterology 2007;50(3):188-192
Pneumatosis cystoides intestinalis is an uncommon condition of unknown etiology, characterized by the presence of multiple gas filled cysts in the gastrointestinal tract. Many different causes of pneumatosis cystoides intestinalis have been proposed, including mechanical, pulmonary, and bacterial causes. Approximately 85% of cases are thought to be secondary to coexisting disorders of the gastrointestinal tract or the respiratory system. The condition has been associated with the therapeutic uses of lactulose, steroids, and various cancer chemotherapeutic regimens. Lactitol is a disaccharide analogue of lactulose which is available as a pure crystalline powder. There are three previous case reports suggestive of lactulose causing pnumatosis intestinalis. We report a case of recurrent pneumatosis cystoides intestinalis associated with benign recurrent pneumoperitoneum developed probably secondary to lactitol therapy.
Adult
;
Cathartics/adverse effects/therapeutic use
;
Female
;
Humans
;
Pneumatosis Cystoides Intestinalis/*diagnosis/etiology/radiography
;
Pneumoperitoneum/complications/*diagnosis
;
Recurrence
;
Sugar Alcohols/adverse effects/therapeutic use
;
Tomography, X-Ray Computed
2.A Case of Pneumatosis Intestinalis Associated with Sunitinib Treatment for Renal Cell Carcinoma.
Yoo A CHOI ; Eun Hui SIM ; Kyoung Eun LEE ; Sun Young KO ; Min Ji SEO ; Young Jun YANG ; Ji Chan PARK ; Suk Young PARK
The Korean Journal of Gastroenterology 2013;61(6):347-350
Sunitinib as a multitarget tyrosine kinase inhibitor is one of the anti-tumor agents, approved by the United States Food and Drug Administration to use treat gastrointestinal stromal tumor and metastatic renal cell carcinoma. The agent is known to commonly induce adverse reactions such as fatigue, nausea, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity, reduciton in cardiac output of left ventricle, and hypothyroidism. However, it has been reported to rarely induce adverse reactions such as nephrotic syndrome and irreversible reduction in renal functions, and cases of intestinal perforation or pneumatosis interstinalis as such reactions have been consistently reported. In this report, a 66-year old man showing abdominal pain had renal cell carcinoma and history of sunitinib at a dosage of 50 mg/day on a 4-weeks-on, 2-weeks-off schedule. Seven days after the third cycle he was referred to the hospital because of abdominal pain. Computed tomography showed pneumoperitoneum with linear pneumatosis intestinalis in his small bowel. The patient underwent surgical exploration that confirmed the pneumatosis intestinalis at 100 cm distal to Treitz's ligament. We report a rare case of intestinal perforation with pneumatosis intestinalis after administration of sunitinib to a patient with metastatic renal cell carcinoma.
Aged
;
Antineoplastic Agents/adverse effects/*therapeutic use
;
Carcinoma, Renal Cell/*drug therapy
;
Drug Administration Schedule
;
Humans
;
Indoles/adverse effects/*therapeutic use
;
Intestinal Perforation/*diagnosis/etiology/surgery
;
Kidney Neoplasms/*drug therapy
;
Lung/radiography
;
Male
;
Pneumatosis Cystoides Intestinalis/*diagnosis/etiology
;
Positron-Emission Tomography
;
Pyrroles/adverse effects/*therapeutic use
;
Tomography, X-Ray Computed